Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Download PDF
May 3, 2016
/
News
Share
the Post
Related
Posts
Updated WHO screening, care and treatment of persons with hepatitis C infection_ April 2016.
Four Indian generic companies take sub license from MPP on daclatasvir
A two pager of what you need to know of Sofosbuvir
New WHO guideline on care and treatment of chronic hepatitis C
Strategies to Secure Access to Generic HCV Medicines
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
Support letter for inclusion of Daclatasvir on 4th March, 2015.
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
